Prostate Cancer | Specialty

Dr. Mathew Hall on Risks and Benefits of PSA Screening

April 29th 2015

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses prostate cancer screening.

Dr. Sartor on Sequencing Therapies in Prostate Cancer

April 24th 2015

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses sequencing therapies and potential targets in prostate cancer.

Olaparib Nears 90% Response in Molecular Subgroup of mCRPC

April 21st 2015

Treatment with olaparib demonstrated a durable overall response rate of 87.5% in a biomarker-defined subgroup of men with pretreated sporadic metastatic castration-resistant prostate cancer in a phase II multi-step adaptive trial.

Tasquinimod Development in mCRPC Halted After Phase III Study Falls Short

April 16th 2015

Topline results announced today from the phase III Swedish trial 10TASQ10 demonstrated that tasquinimod failed to extend overall survival in men with metastatic castrate-resistant prostate cancer.

Dr. Michalski on Escalated Dose Radiation Therapy in Prostate Cancer

April 14th 2015

Jeff Michalski, MD, professor, vice chair of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses results of a study which compared standard dose radiation therapy to escalated dose for patients with intermediate-risk prostate cancer.

New Rucaparib Designation, STRIVE Trial, 5-Year Ipilimumab Data, and More

April 12th 2015

CTC Panel Shows Promise as Survival Surrogate in CRPC

April 7th 2015

A biomarker panel containing circulating tumor cell number and LDH level was shown to be a surrogate for overall survival in patients with metastatic castration-resistant prostate cancer.

Abiraterone Label Expanded, Phase III Melanoma Data, SGR Repeal, and More

April 3rd 2015

STRIVE Data Further Demonstrate PFS Benefit With Enzalutamide Over Bicalutamide

April 2nd 2015

Treatment with enzalutamide reduced the risk of progression by 76% compared with bicalutamide in men with castration-resistant prostate cancer.

Dr. Garcia on Challenges With Immunotherapy in Prostate Cancer

April 1st 2015

Jorge A. Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the challenges with immunotherapy in prostate cancer.

FDA Approves Abiraterone Pre-Chemo mCRPC Label Update

March 30th 2015

The FDA has updated the label for abiraterone acetate plus prednisone to include significant overall survival data from the final analysis of the phase III COU-AA-302 study.

Thomas Neville's Dynamic Analysis of Multiple PSA Results Leads to Better Reliability, Insights

March 28th 2015

A new phase begins for Thomas Neville, PhD, a Yale and Stanford-trained engineer and economist who worked in energy before a prostate cancer diagnosis drew him into medical research.

PREVAIL, TERRAIN Updates Show Improved OS With Enzalutamide

March 24th 2015

Two studies investigating enzalutamide in men with early stage metastatic castration-resistant prostate cancer further confirmed the overall survival and progression-free survival benefit of the agent over placebo.

Phase III Ibrutinib Findings, Prostate Cancer Congress, and More

March 19th 2015

Prostate Cancer: Which Guidelines

March 19th 2015

Changes in NCCN Guideline: Affecting First-Line

March 19th 2015

Considerations in Treatment Selection

March 19th 2015

Sipuleucel-T: Evidence-based Use

March 19th 2015

Changes in NCCN Guideline: Affecting Second-Line

March 19th 2015

A Review of Bone-Targeted Therapies

March 19th 2015